Novo Nordisk looks to build existing business in Japan in launchless 2012
This article was originally published in Scrip
Novo Nordisk is developing what it views as its strongest ever pipeline in Japan, but faces a lull in new product launches this year before the series of new products begins to reach the market.
You may also be interested in...
Positive clinical results pave path forward for Japanese firm’s potential istradefylline successor.
Curon thinks tenalisib can offer a differentiated and safe new therapy for hematologic cancers such as multiple forms of lymphoma. Axis and PharmaEssentia team up on TCR therapy R&D in Taiwan.
Recent moves show Chinese biotech firms are increasingly looking to go global by recruiting world-class development talent, and J&J names new APAC pharma head.